Hospital resource utilization in patients with generalized myasthenia gravis treated with nipocalimab: results from the VIVACITY-MG3 study.

TL;DR

Nipocalimab plus standard-of-care reduced hospital admissions/ED visits and associated costs by approximately 50-68% compared to placebo in seropositive generalized myasthenia gravis patients. Clinical deterioration and high baseline respiratory disease severity independently predicted high-cost hospitalization events.

Key findings

• Nipocalimab reduced all-cause and gMG-related hospital days by 60% and 68% respectively, with estimated cost offsets of $10,860-$13,253 per patient per year
• Incidence rate of hospitalization/ED visits was 51% numerically lower with nipocalimab, with shorter mean hospital stays (8.4 vs 14.6 days for all-cause)
• Worsening MG-ADL scores and higher baseline QMG respiratory scores independently predicted high-cost hospital events
• Open-label extension data showed 64% reduction in hospital days when patients switched from placebo to nipocalimab

Why this matters at the bedside

Demonstrates nipocalimab's impact on reducing acute care utilization and hospitalization burden in generalized myasthenia gravis, with direct cost implications and identification of patients at highest risk for costly events.